May 21, 2012
Hisamitsu Pharmaceutical announced on May 18 that it filed a new drug application (NDA) on May 17 for a transdermal formulation for the over active bladder treatment HOB-294 (oxybutynin HCl). Generic versions of oxybutynin have already been available (oral tablets)...read more